OBJECTIVE:Ribavirin improves treatment response to pegylated-interferon (PEG-IFN) in chronic hepatitis C but the mechanism remains controversial. We studied correlates of response and mechanism of action of ribavirin in treatment of hepatitis C. DESIGN: 70 treatment-naive patients were randomised to 4 weeks of ribavirin (1000-1200 mg/d) or none, followed by PEG-IFNα-2a and ribavirin at standard doses and durations. Patients were also randomised to a liver biopsy 24 h before or 6 h after starting PEG-IFN. Hepatic gene expression was assessed by microarray and interferon-stimulated gene (ISG) expression quantified by nCounter platform. Temporal changes in ISG expression were assessed by qPCR in peripheral-blood mononuclear cells (PBMC) and by serum levels of IP-10. RESULTS: After 4 weeks of ribavirin monotherapy, hepatitis C virus (HCV) levels decreased by 0.5±0.5 log10 (p=0.009 vs controls) and ALT by 33% (p<0.001). Ribavirin pretreatment, while modestly augmenting ISG induction by PEG-IFN, did not modify the virological response to subsequent PEG-IFN and ribavirin treatment. However, biochemical, but not virological, response to ribavirin monotherapy predicted response to subsequent combination treatment (rapid virological response, 71% in biochemical responders vs 22% non-responders, p=0.01; early virological response, 100% vs 68%, p=0.03; sustained virological response 83% vs 41%, p=0.053). Ribavirin monotherapy lowered serum IP-10 levels but had no effect on ISG expression in PBMC. CONCLUSIONS:Ribavirin is a weak antiviral but its clinical effect seems to be mediated by a separate, indirect mechanism, which may act to reset IFN-responsiveness in HCV-infected liver.
RCT Entities:
OBJECTIVE:Ribavirin improves treatment response to pegylated-interferon (PEG-IFN) in chronic hepatitis C but the mechanism remains controversial. We studied correlates of response and mechanism of action of ribavirin in treatment of hepatitis C. DESIGN: 70 treatment-naive patients were randomised to 4 weeks of ribavirin (1000-1200 mg/d) or none, followed by PEG-IFNα-2a and ribavirin at standard doses and durations. Patients were also randomised to a liver biopsy 24 h before or 6 h after starting PEG-IFN. Hepatic gene expression was assessed by microarray and interferon-stimulated gene (ISG) expression quantified by nCounter platform. Temporal changes in ISG expression were assessed by qPCR in peripheral-blood mononuclear cells (PBMC) and by serum levels of IP-10. RESULTS: After 4 weeks of ribavirin monotherapy, hepatitis C virus (HCV) levels decreased by 0.5±0.5 log10 (p=0.009 vs controls) and ALT by 33% (p<0.001). Ribavirin pretreatment, while modestly augmenting ISG induction by PEG-IFN, did not modify the virological response to subsequent PEG-IFN and ribavirin treatment. However, biochemical, but not virological, response to ribavirin monotherapy predicted response to subsequent combination treatment (rapid virological response, 71% in biochemical responders vs 22% non-responders, p=0.01; early virological response, 100% vs 68%, p=0.03; sustained virological response 83% vs 41%, p=0.053). Ribavirin monotherapy lowered serum IP-10 levels but had no effect on ISG expression in PBMC. CONCLUSIONS:Ribavirin is a weak antiviral but its clinical effect seems to be mediated by a separate, indirect mechanism, which may act to reset IFN-responsiveness in HCV-infected liver.
Authors: Robert E Lanford; Bernadette Guerra; Helen Lee; Deborah Chavez; Kathleen M Brasky; Catherine B Bigger Journal: Hepatology Date: 2006-05 Impact factor: 17.425
Authors: Milton W Taylor; Takuma Tsukahara; Leonid Brodsky; Joel Schaley; Corneliu Sanda; Matthew J Stephens; Jeanette N McClintick; Howard J Edenberg; Lang Li; John E Tavis; Charles Howell; Steven H Belle Journal: J Virol Date: 2007-01-31 Impact factor: 5.103
Authors: Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu Journal: N Engl J Med Date: 2002-09-26 Impact factor: 91.245
Authors: Jay H Hoofnagle; Marc G Ghany; David E Kleiner; Edward Doo; Theo Heller; Kittichai Promrat; Janus Ong; Farooq Khokhar; Alejandro Soza; David Herion; Yoon Park; James E Everhart; T Jake Liang Journal: Hepatology Date: 2003-07 Impact factor: 17.425
Authors: A M Di Bisceglie; H S Conjeevaram; M W Fried; R Sallie; Y Park; C Yurdaydin; M Swain; D E Kleiner; K Mahaney; J H Hoofnagle Journal: Ann Intern Med Date: 1995-12-15 Impact factor: 25.391
Authors: Julia Dietz; Sven-Eric Schelhorn; Daniel Fitting; Ulrike Mihm; Simone Susser; Martin-Walter Welker; Caterina Füller; Martin Däumer; Gerlinde Teuber; Heiner Wedemeyer; Thomas Berg; Thomas Lengauer; Stefan Zeuzem; Eva Herrmann; Christoph Sarrazin Journal: J Virol Date: 2013-03-27 Impact factor: 5.103
Authors: Mario Rossi; Lu Zhu; Sara M McMillin; Sai Prasad Pydi; Shanu Jain; Lei Wang; Yinghong Cui; Regina J Lee; Amanda H Cohen; Hideaki Kaneto; Morris J Birnbaum; Yanling Ma; Yaron Rotman; Jie Liu; Travis J Cyphert; Toren Finkel; Owen P McGuinness; Jürgen Wess Journal: J Clin Invest Date: 2018-01-16 Impact factor: 14.808
Authors: Hanna Kim; Adriana A de Jesus; Stephen R Brooks; Yin Liu; Yan Huang; Rachel VanTries; Gina A Montealegre Sanchez; Yaron Rotman; Massimo Gadina; Raphaela Goldbach-Mansky Journal: J Interferon Cytokine Res Date: 2018-04 Impact factor: 2.607